Literature DB >> 18413770

The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.

Lisa M Ebert1, Bee Shin Tan, Judy Browning, Suzanne Svobodova, Sarah E Russell, Naomi Kirkpatrick, Craig Gedye, Denis Moss, Sweet Ping Ng, Duncan MacGregor, Ian D Davis, Jonathan Cebon, Weisan Chen.   

Abstract

FoxP3 is a member of the forkhead family of transcription factors critically involved in the development and function of CD25(+) regulatory T cells (Treg). Until recently, FoxP3 expression was thought to be restricted to the T-cell lineage. However, using immunohistochemistry and flow cytometric analysis of human melanoma tissue, we detected FoxP3 expression not only in the tumor infiltrating Treg but also in the melanoma cells themselves. FoxP3 is also widely expressed by established human melanoma cell lines (as determined by flow cytometry, PCR, and Western blot), as well as cell lines derived from other solid tumors. Normal B cells do not express FoxP3; however, expression could be induced after transformation with EBV in vitro and in vivo, suggesting that malignant transformation of healthy cells can induce FoxP3. In addition, a FOXP3 mRNA variant lacking exons 3 and 4 was identified in tumor cell lines but was absent from Treg. Interestingly, this alternative splicing event introduces a translation frame-shift that is predicted to encode a novel protein. Together, our results show that FoxP3, a key regulator of immune suppression, is not only expressed by Treg but also by melanoma cells, EBV-transformed B cells, and a wide variety of tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413770     DOI: 10.1158/0008-5472.CAN-07-5664

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  78 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Stephan Lang; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2011-04-13       Impact factor: 2.303

Review 3.  The "O" class: crafting clinical care with FoxO transcription factors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 4.  FOXP3 as an X-linked tumor suppressor.

Authors:  Lizhong Wang; Runhua Liu; Mark Ribick; Pan Zheng; Yang Liu
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

5.  FoxP3: a life beyond regulatory T cells.

Authors:  Yang Liu; Pan Zheng
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

6.  Study of circulating antibodies against CD25 and FOXP3 in breast cancer.

Authors:  Tong Liu; Yan-ni Song; Qing-Yu Shi; Yang Liu; Xia-nan Bai; Da Pang
Journal:  Tumour Biol       Date:  2013-12-18

7.  Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells.

Authors:  Biao Zhang; Yuchao Dou; Xinnv Xu; Xiuyu Wang; Bin Xu; Jixiang Du; Qiong Wang; Qingguo Li; Jinhuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

8.  Cancer Vaccines 2007. Cancer and HIV Vaccines: Shared Lessons. October 4-6, 2007, New York, USA. Abstracts.

Authors: 
Journal:  Cancer Immun       Date:  2008

9.  High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma.

Authors:  Noyko Stanilov; Lyuba Miteva; Nikolay Mintchev; Spaska Stanilova
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.